Brandon Whitefield is a seasoned medicinal chemist with over 16 years of experience, currently serving as a Senior Principal Scientist at Innovo Therapeutics. In this pivotal role, Brandon leverages his extensive expertise in small molecule inhibitors, particularly in the realm of kinase targets and PROTAC...
Brandon Whitefield is a seasoned medicinal chemist with over 16 years of experience, currently serving as a Senior Principal Scientist at Innovo Therapeutics. In this pivotal role, Brandon leverages his extensive expertise in small molecule inhibitors, particularly in the realm of kinase targets and PROTAC (Proteolysis Targeting Chimeras) design and synthesis. His deep understanding of medicinal chemistry enables him to lead the charge on multiple novel oncology projects, where he plays a crucial role in the design and synthesis of innovative compounds aimed at addressing unmet medical needs in cancer treatment.
Brandon's responsibilities encompass a wide array of functions, including the management of Contract Research Organizations (CROs) and overseeing both small-scale intermediate management and large-scale toxicology batch contract management. His adeptness in navigating the complexities of drug development—from early hit identification through to pre-clinical drug candidate delivery—demonstrates his comprehensive understanding of the pharmaceutical landscape. He excels in cross-site collaboration, ensuring that projects progress smoothly and efficiently across domestic and international teams.
His proficiency in organic synthesis and laboratory skills is complemented by his strategic vision for drug discovery, making him an invaluable asset to Innovo Therapeutics. Brandon's commitment to advancing oncology therapeutics is reflected in his ability to drive projects forward while fostering a collaborative environment that encourages innovation and scientific excellence. As he continues to contribute to groundbreaking research, Brandon remains dedicated to pushing the boundaries of medicinal chemistry and improving patient outcomes in the fight against cancer.
